{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:38:19Z","timestamp":1792028299242,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,9,21]],"date-time":"2007-09-21T00:00:00Z","timestamp":1190332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1038\/sj.eye.6702980","type":"journal-article","created":{"date-parts":[[2007,9,21]],"date-time":"2007-09-21T12:27:06Z","timestamp":1190377626000},"page":"117-123","source":"Crossref","is-referenced-by-count":89,"title":["Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up"],"prefix":"10.1038","volume":"23","author":[{"given":"J F","family":"Arevalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J G","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Saravia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C F","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,21]]},"reference":[{"key":"BF6702980_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/414782a","volume":"414","author":"P Zimmet","year":"2001","unstructured":"Zimmet P, Alberti KG, Shaw J . Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782\u2013787.","journal-title":"Nature"},{"key":"BF6702980_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445\u2013450.","journal-title":"Am J Ophthalmol"},{"key":"BF6702980_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480\u20131487.","journal-title":"N Engl J Med"},{"key":"BF6702980_CR4","first-page":"638","volume":"72","author":"J Pe'er","year":"1995","unstructured":"Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E . Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72: 638\u2013645.","journal-title":"Lab Invest"},{"key":"BF6702980_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ajo.2004.10.004","volume":"139","author":"D Watanabe","year":"2005","unstructured":"Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139: 476\u2013481.","journal-title":"Am J Ophthalmol"},{"key":"BF6702980_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0002-9394(01)01381-2","volume":"133","author":"MJ Tolentino","year":"2002","unstructured":"Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA . Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133: 373\u2013385.","journal-title":"Am J Ophthalmol"},{"key":"BF6702980_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","volume":"113","author":"AP Adamis","year":"2006","unstructured":"Adamis AP, Altaweel M, Bressler NM, Cunningham Jr ET, Davis MD, Goldbaum M et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23\u201328.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL . Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275\u2013278.","journal-title":"Retina"},{"key":"BF6702980_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391\u2013400.","journal-title":"Nat Rev Drug Discov"},{"key":"BF6702980_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS . Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035\u20131047.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363\u2013372.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00006982-200603000-00005","volume":"26","author":"D Iturralde","year":"2006","unstructured":"Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279\u2013284.","journal-title":"Retina"},{"key":"BF6702980_CR13","first-page":"1695.e1","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695.e1\u20131695.e15.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","volume":"142","author":"JO Mason III","year":"2006","unstructured":"Mason III JO, Nixon PA, White MF . Intravitreal injection of bevacizumab (avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 685\u2013688.","journal-title":"Am J Ophthalmol"},{"key":"BF6702980_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/00006982-200603000-00003","volume":"26","author":"RK Maturi","year":"2006","unstructured":"Maturi RK, Bleau LA, Wilson DL . Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 270\u2013274.","journal-title":"Retina"},{"key":"BF6702980_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262\u2013269.","journal-title":"Retina"},{"key":"BF6702980_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","volume":"26","author":"RP Manzano","year":"2006","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M . Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257\u2013261.","journal-title":"Retina"},{"key":"BF6702980_CR18","first-page":"23","volume":"30","author":"SC Kaufman","year":"1989","unstructured":"Kaufman SC, Ferris III FL, Seigel DG, Davis MD, DeMets DL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy: diabetic retinopathy study report 13. Invest Ophthalmol Vis Sci 1989; 30: 23\u201328.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BF6702980_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0002-9394(98)00309-2","volume":"127","author":"DS Fong","year":"1999","unstructured":"Fong DS, Ferris III FL, Davis MD, Chew EY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report No. 24. Am J Ophthalmol 1999; 127: 137\u2013141.","journal-title":"Am J Ophthalmol"},{"key":"BF6702980_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/bjo.73.3.197","volume":"73","author":"GW Aylward","year":"1989","unstructured":"Aylward GW, Pearson RV, Jagger JD, Hamilton AM . Extensive argon laser photocoagulation in the treatment of proliferative diabetic retinopathy. Br J Ophthalmol 1989; 73: 197\u2013201.","journal-title":"Br J Ophthalmol"},{"key":"BF6702980_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0161-6420(82)34734-X","volume":"89","author":"BH Doft","year":"1982","unstructured":"Doft BH, Blankenship GW . Single vs multiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1982; 89: 772\u2013779.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0161-6420(87)33526-2","volume":"94","author":"FL Ferris III","year":"1987","unstructured":"Ferris III FL, Podgor MJ, Davis MD . Macular edema in diabetic retinopathy study (DRS): DRS report number 12. Ophthalmology 1987; 94: 754\u2013760.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0161-6420(85)34016-2","volume":"92","author":"HR McDonald","year":"1985","unstructured":"McDonald HR, Schatz H . Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1985; 92: 388\u2013393.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR24","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ophtha.2003.05.008","volume":"110","author":"M Shimura","year":"2003","unstructured":"Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M . Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110: 2386\u20132394.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara N . VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795\u2013803.","journal-title":"Nat Rev Cancer"},{"key":"BF6702980_CR26","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N . Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306\u20131309.","journal-title":"Science"},{"key":"BF6702980_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J . Vascular specific growth factor and blood vessel formation. Nature 2000; 407: 242\u2013248.","journal-title":"Nature"},{"key":"BF6702980_CR28","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak HF . Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368\u20134380.","journal-title":"J Clin Oncol"},{"key":"BF6702980_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","volume":"26","author":"RL Avery","year":"2006","unstructured":"Avery RL . Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352\u2013354.","journal-title":"Retina"},{"key":"BF6702980_CR30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1442-9071.2006.01378.x","volume":"34","author":"TW Isaacs","year":"2006","unstructured":"Isaacs TW, Barry C . Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006; 34: 802\u2013803.","journal-title":"Clin Experiment Ophthalmol"},{"key":"BF6702980_CR31","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1001\/archopht.124.9.1365","volume":"124","author":"SM Friedlander","year":"2006","unstructured":"Friedlander SM, Welch RM . Vanishing disc neovascularization following intravitreal bevacizumab (Avastin) injection. Arch Ophthalmol 2006; 124: 1365.","journal-title":"Arch Ophthalmol"},{"key":"BF6702980_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/01.iae.0000225351.87205.69","volume":"26","author":"E Chen","year":"2006","unstructured":"Chen E, Park CH . Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26: 699\u2013700.","journal-title":"Retina"},{"key":"BF6702980_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0161-6420(81)34978-1","volume":"88","author":"Diabetic Retinopathy Study Research Group","year":"1981","unstructured":"Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of diabetic retinopathy study (DRS): DRS report 8. Ophthalmology 1981; 88: 583\u2013600.","journal-title":"Ophthalmology"},{"key":"BF6702980_CR34","doi-asserted-by":"crossref","unstructured":"Randomized comparison of krypton vs argon scatter photocoagulation for diabetic disc neovascularization: the krypton argon regression neovascularization study report number 1. Ophthalmology 1993; 100: 1655\u20131664.","DOI":"10.1016\/S0161-6420(93)31421-1"},{"key":"BF6702980_CR35","first-page":"1204","volume":"43","author":"A Nonaka","year":"2002","unstructured":"Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Nishijima K, Kamizuru H et al. Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. Invest Ophthalmol Vis Sci 2002; 43: 1204\u20131209.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BF6702980_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00006982-199901000-00010","volume":"19","author":"A Tsujikawa","year":"1999","unstructured":"Tsujikawa A, Kiryu J, Dong J, Yasukawa T, Suzuma I, Takagi H et al. Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer. Retina 1999; 19: 59\u201364.","journal-title":"Retina"},{"key":"BF6702980_CR37","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0161-6420(03)01004-2","volume":"110","author":"AP Schachat","year":"2003","unstructured":"Schachat AP, Chambers WA, Liesegang TJ, Albert DA . Safe and effective. Ophthalmology 2003; 110: 2073\u20132074.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6702980.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6702980","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6702980.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:31:06Z","timestamp":1684413066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6702980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,21]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["BF6702980"],"URL":"https:\/\/doi.org\/10.1038\/sj.eye.6702980","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,21]]}}}